The DAD Study Group investigated the association between exposure to protease inhibitors (PIs) and nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and the risk of myocardial infarction (MI) in HIV-1 infected patients. The study followed 23,437 patients over 94,469 person-years, finding that MI incidence increased from 1.53 to 6.01 per 1000 person-years with longer PI exposure. After adjusting for other factors, PI exposure was associated with a 1.16-fold increased MI risk per year, while NNRTI exposure showed no significant association. Adjusting for lipid levels reduced the PI risk to 1.10 and NNRTI risk to 1.00. The study concluded that increased PI exposure is linked to higher MI risk, possibly due to dyslipidemia, while NNRTIs showed no such association. The study highlights the need for careful monitoring of cardiovascular risks in HIV patients on antiretroviral therapy.The DAD Study Group investigated the association between exposure to protease inhibitors (PIs) and nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and the risk of myocardial infarction (MI) in HIV-1 infected patients. The study followed 23,437 patients over 94,469 person-years, finding that MI incidence increased from 1.53 to 6.01 per 1000 person-years with longer PI exposure. After adjusting for other factors, PI exposure was associated with a 1.16-fold increased MI risk per year, while NNRTI exposure showed no significant association. Adjusting for lipid levels reduced the PI risk to 1.10 and NNRTI risk to 1.00. The study concluded that increased PI exposure is linked to higher MI risk, possibly due to dyslipidemia, while NNRTIs showed no such association. The study highlights the need for careful monitoring of cardiovascular risks in HIV patients on antiretroviral therapy.